Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript by Kote-Jarai, Zsofia et al.
ORIGINAL INVESTIGATION
Identification of a novel prostate cancer susceptibility variant
in the KLK3 gene transcript
Z. Kote-Jarai • A. Amin Al Olama • D. Leongamornlert • M. Tymrakiewicz • E. Saunders • M. Guy •
G. G. Giles • G. Severi • M. Southey • J. L. Hopper • K. C. Sit • J. M. Harris • J. Batra • A. B. Spurdle •
J. A. Clements • F. Hamdy • D. Neal • J. Donovan • K. Muir • P. D. P. Pharoah • S. J. Chanock •
N. Brown • S. Benlloch • E. Castro • N. Mahmud • L. O’Brien • A. Hall • E. Sawyer • R. Wilkinson •
D. F. Easton • R. A. Eeles
Received: 17 January 2011 / Accepted: 14 March 2011 / Published online: 5 April 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Genome-wide association studies (GWAS)
have identified more than 30 prostate cancer (PrCa) sus-
ceptibility loci. One of these (rs2735839) is located close to
a plausible candidate susceptibility gene, KLK3, which
encodes prostate-specific antigen (PSA). PSA is widely
used as a biomarker for PrCa detection and disease moni-
toring. To refine the association between PrCa and variants
in this region, we used genotyping data from a two-stage
GWAS using samples from the UK and Australia, and the
Cancer Genetic Markers of Susceptibility (CGEMS) study.
Genotypes were imputed for 197 and 312 single nucleotide
polymorphisms (SNPs) from HapMap2 and the 1000
Genome Project, respectively. The most significant asso-
ciation with PrCa was with a previously unidentified SNP,
rs17632542 (combined P = 3.9 9 10-22). This association
was confirmed by direct genotyping in three stages of the
UK/Australian GWAS, involving 10,405 cases and 10,681
controls (combined P = 1.9 9 10-34). rs17632542 is also
shown to be associated with PSA levels and it is a non-
synonymous coding SNP (Ile179Thr) in KLK3. Using
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molecular dynamic simulation, we showed evidence that
this variant has the potential to introduce alterations in the
protein or affect RNA splicing. We propose that
rs17632542 may directly influence PrCa risk.
Background
Prostate cancer (PrCa) is the most common cancer in men
living in the Western world, with a lifetime risk of
approximately 1 in 8 for men in Europe and the USA
(http://www.info.cancerresearchuk.org/cancerstats/types/
prostate/). Its aetiology remains poorly understood. The
increased risk of PrCa for men with a family history is
consistent with variation in genetic susceptibility to the
disease (Edwards and Eeles 2004). Genome-wide associa-
tion studies (GWAS) are a proven way to identify common
disease susceptibility alleles. Thus far, such studies have
identified SNPs associated with prostate cancer in more
than 30 independent regions (Liu et al. 2010). We previ-
ously conducted a GWAS in two stages and identified
SNPs in seven regions associated with PrCa risk (Eeles
et al. 2008). One of these SNPs, rs2735839 on 19q13.3, lies
within an LD block of 34 kb, containing the kallikrein
genes, KLK3 and KLK2 (combined stage 1 and 2
P = 2.3 9 10-17). This SNP was also shown to be asso-
ciated with serum PSA level; however, an association with
PrCa has been demonstrated using samples not ascertained
by PSA screening, suggesting that the association is not
solely due to selection of cases with elevated PSA and
controls with a low PSA level (Ahn et al. 2008).
KLK3 encodes prostate-specific antigen (PSA), a mem-
ber of the kallikrein family of serine proteases. Its main
physiological function is to cleave semenogelins in the
seminal coagulum, thereby regulating sperm motility. Like
other kallikreins, it might also participate in the process of
neoplastic growth and metastasis of PrCa (Lawrence et al.
2010; Paliouras et al. 2007). The expression of PSA is
highly restricted to normal and malignant prostate epithe-
lial cells in men. During tumorigenesis, however, serum
PSA levels tend to be elevated, probably due to the loss of
normal architecture of the gland. For this reason, PSA is
extensively used as a biomarker to screen for and monitor
treatment of PrCa.
The association with rs2735839 implies that one or more
variants in the KLK3 region, correlated with rs2735839, are
directly associated with PrCa risk. In an attempt to identify
such variants, we performed a comprehensive analysis of
SNPs across the region, using a combination of imputation
and further genotyping.
Materials and methods
Samples
Analyses were based on the samples genotyped in first and
second stages of an UK/Australian GWAS, collected as
previously described (Eeles et al. 2008, 2009), together
with a third stage involving a further 4,901 cases and 4,847
controls. Stage 3 samples were selected from UKGPCS as
for stages 1 and 2; from Studies of Epidemiology and Risk
factors in Cancer Heredity (SEARCH), a case–control
study based on the region covered by the Eastern UK
Cancer Registry and Information Centre (ECRIC); and
from the Australian epidemiological studies as in stage 2
(Supplementary Table 1). We also included data from the
Cancer Genetic Markers of Susceptibility (CGEMS) study,
a GWAS of 1,117 PrCa cases and 1,105 controls drawn
from the PLCO study (http://www.cgems.cancer.gov/).
Imputation
To evaluate associations with PrCa for SNPs not included
in genotyping arrays used in the GWAS, we defined a
34 kb LD region that included all SNPs in the region
correlated with the original best hit, rs2735839, at r2 [ 0.1
according to the HapMap Phase II CEU dataset. We then
identified all SNPs in the interval from the HapMap Phase
II as well as SNPs identified through sequencing of Euro-
pean (CEU) samples in the 1000 Genomes study at a fre-
quency of at least 2%. Genotypes for these SNPs in stages
1 and 2 of the UK/Australian GWAS, and the CGEMS
study, were then imputed using MACH 1.0 (http://www.
sph.umich.edu/csg/abecasis/MACH/) and 50 rounds of
imputation. We included SNPs with quality score
(r2) [ 0.3 in the analysis.
Genotyping
SNP rs17632542 was genotyped for stages 1 and 2 samples
by the 50-endonuclease assay (TaqmanTM) using the
ABIPrism 7900HT sequence detection system according to
the manufacturer’s instructions. Primers and probes were
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supplied by Applied Biosystems (http://www.appliedbio
systems.com/) as Assays-By-DesignTM. The Stage 3
genotyping was done using an Illumina Golden Gate Assay
(http://www.illumina.com).
Statistical methods
We assessed associations between each SNP and disease
using a 1 df.
Cochran–Armitage trend test, stratified by GWAS stage
(UK/Australia stage 1, 2 or 3, and CGEMS). For imputed
SNPs, we used the corresponding test based on the esti-
mated allele dose. Odds ratios and confidence limits were
estimated using unconditional logistic regression, stratified
by stage. Tests of homogeneity of the odds ratios across
strata were assessed using likelihood ratio tests. To deter-
mine independently associated SNPs from imputed data,
we identified all SNPs significant at P \ 10-7 from
Table 1 Summary results for 4 SNPs in the KLK3 region at 19q13.3
Markera
Allelesb
Positionc
Stage Per alleled OR (95%CI) Het ORd,e (95%CI) Hom ORd,f (95%CI) P valueg
Stage Combined
rs17632542
T/C
56053569
Stage 1 0.35 (0.30–0.42) 0.35 (0.29–0.43) 0.13 (0.06–0.31) 2.6 9 10-29
Stage 2 0.78 (0.68–0.90) 0.79 (0.68–0.91) 0.53 (0.25–1.13) 0.0004 S1 and 2
1.6 9 10-24
Stage3 0.65 (0.57–0.74) 0.65 (0.56–0.74) 0.47 (0.23–0.93) 1.2 9 10-10 S 1, 2 and 3
3.6 9 10-33
S1, 2, 3 and CGEMS
1.9 9 10-34
Imputation stage 1 3.1 9 10-25
Imputation stage 2 5.6 9 10-4 S2 ? CGEMS
2.5 9 10-5
Imputation CGEMS 0.01 S1, 2 and CGEMS
3.9 9 10-22
rs2735839
G/A
56056435
Stage 1 0.56 (0.50–0.64) 0.58 (0.50–0.67) 0.29 (0.19–0.43) 8.2 9 10-20
Stage 2 0.84 (0.77–0.93) 0.83 (0.74–0.92) 0.80 (0.56–1.14) 0.001 S1 and 2
2.3 9 10-17
Stage 3 0.80 (0.73–0.88) 0.78 (0.70–0.86) 0.74 (0.54–1.02) 1.1 9 10-6 S 1, 2 and 3
5.4 9 10-22
S 1, 2, 3 and CGEMS
1.1 9 10-22
rs266849
A/G
56040902
Stage 1 0.62 (0.55–0.69) 0.60 (0.52–0.69) 0.42 (0.30–0.58) 1.7 9 10-16
Stage 2 0.95 (0.87–1.03) 0.88 (0.79–0.98) 1.15 (0.89–1.49) 0.23 S1 and 2
2.1 9 10-9
Stage3 0.81 (0.74–0.87) 0.81 (0.74–0.89) 0.64 (0.50–0.82) 1.2 9 10-7 S 1, 2 and 3
1.3 9 10-15
S1, 2, 3 and CGEMS
1.4 9 10-14
rs1058205
T/C
56055210
Stage 1 0.59 (0.52–0.66) 0.60 (0.52–0.69) 0.33 (0.24–0.45) 4.7 9 10-20
Stage 2 0.85 (0.78–0.93) 0.82 (0.74–0.91) 0.85 (0.64–1.11) 0.0004 S1 and 2
1.6 9 10-17
Stage3 0.81 (0.75–0.88) 0.81 (0.73–0.89) 0.68 (0.53–0.89) 8.2 9 10-7 S 1, 2 and 3
3.0 9 10-22
S1, 2, 3 and CGEMS
2.8 9 10-23
rs17632542 is the most strongly associated SNP in this study. rs273539 was the most strongly associated SNP in the original GWAS. rs266849
and rs1058205 also reached P \ 10-7 in the original GWAS
a dbSNP rs number, b major/minor allele, based on the frequencies in stage 1 controls, c build 36 position, d OR odds ratio, e OR in
heterozygotes, relative to common homozygotes, f OR in homozygotes, relative to common homozygotes, g Cochran–Armitage test for trend
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combined stages 1, 2 and CGEMS and used forward and
backward stepwise logistic regression, based on estimated
allele dose. SNPs were included in the model if they were
significant at P \ 0.001 after adjustment for other SNPs in
the model. For the genotyped SNPs, we identified all SNPs
significant at P \ 10-7 in the stages 1, 2, 3 and CGEMS
data combined and used forward and backward stepwise
logistic regression.
The associations of SNP genotypes with PSA level were
assessed using linear regression, after log transformation of
PSA level to reduce skewness. Analyses were performed in
R and STATA.
Molecular dynamics modelling the structure of PSA
Potential conformations of the original and mutated crystal
structure models were investigated using energy minimi-
sation and force field (Goodford 1985). To gain further
insights into the effects of substitution at Ile179 we simu-
lated solvated Ile179 and Ile179Thr. Structure files were
generated using Visual Molecular Dynamics (VMD)
(Humphrey et al. 1996). The system was equilibrated using
Nanoscale Molecular Dynamics (NAMD) (Phillips et al.
2005) and simulated using ACEMD (Giupponi et al. 2008)
with the Chemistry at HARvard Molecular Mechanics
(CHARMM) (Brooks et al. 2009) force field. Ten inde-
pendent simulations were carried out for both variants
which were then analysed to determine the models’ aver-
age energies.
Results and discussion
We defined a 34-kb region on 19q13.3 based on HapMap
phase II CEU data that included all SNPs correlated with
rs2735839, the most strongly associated SNP in the
GWAS, at r2 [ 0.1. In this region, we identified 197 SNPs
in HapMap2 and 312 SNPs in the 1000 Genomes Project.
Genotypes for these SNPs were imputed for subjects in
stages 1 and 2 of the UK/Australian GWAS and CGEMS.
Based on the combined results, we identified 35 SNPs
associated with PrCa at P \ 10-7. The most statistically
significant associated SNPs were rs17632542 and
rs62113212 (P = 3.0 9 10-24 and P = 2.2 9 10-24,
respectively, Supplementary Table 2). These two SNPs
were strongly correlated with one another (r2 = 0.99 in
HapMap CEU and r2 = 0.75 in 1000 Genomes, Supple-
mentary Table 3); neither of these SNPs was genotyped in
the original GWAS.
To further evaluate these associations, we genotyped
rs17632542 directly for the stages 1 and 2 sample set
(5,504 cases and 5,834 controls) using a Taqman assay. We
also genotyped rs17632542 in a further set of 4,901 PrCa
cases and 4,847 controls (unselected for PSA) as part of an
Illumina Golden Gate Assay (stage 3). We also genotyped
the original associated SNP, rs2735839, and two other
SNPs (rs266849 and rs1058205) that reached P \ 10-7 in
the original GWAS stages 1 and 2. The estimated per-allele
ORs for rs17632542 were similar to those estimated from
the imputed data, and the statistical significance was fur-
ther increased, stage 1 per allele OR 0.35 (95% CI
0.30–0.42) P = 2.6 9 10-29; stage 2 per allele OR 0.78
(95% CI 0.68–0.90) P = 4 9 10-4; stage 3 per allele OR
0.65 (95% CI 0.57–0.74), P = 4.2 9 10-10; combined
P = 1.9 9 10-34 over all stages. The estimated OR in
homozygotes for the C allele was lower than in heterozy-
gotes in all stages, in a matter consistent with a log-additive
allele dose model (Table 1). As expected, the estimated
effected size was larger in stage 1, reflecting the selection
of cases for family history of disease and the controls for
low PSA (see ‘‘Materials and methods’’), but the estimated
ORs in stages 2 and 3 were similar.
Table 2 Stepwise logistic regression analysis of 7 SNPs in this region associated with PrCa risk at P \ 10-7 (stages 1, 2, 3 and CGEMS)
SNPs in the model OR (95%CI) Model
with all SNPs
P value Model
with all SNPs
Final model
OR (95% CI)a
Final model
P value
rs2735839 0.53 (0.06–4.62) 0.57
rs2569735 1.93 (0.22–16.90) 0.55
rs1058205 0.87 (0.77–0.99) 0.03
rs2659122 1.07 (1.00–1.15) 0.07
rs17632542 0.69 (0.62–0.76) 8.1 9 10-13 0.66 (0.61–0.72) 2.3 9 10-23
rs266849 0.95 (0.85–1.06) 0.34 0.91 (0.86–0.96) 0.001
rs2659051 0.96 (0.85–1.08) 0.52
SNPs retained in the model if significant at P \ 10-3
We have used the combined data from stages 1, 2, 3 and CGEMS
a Forward and backward stepwise regression converge to the same model
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In a multiple logistic regression analysis, rs17632542
remained significant after adjustment for rs2735839
(P = 8.6 9 10-14) based on all stages combined, whereas
rs2735839 showed weaker association after adjustment for
rs17632542 (P = 0.02).
To determine whether there are additional SNPs in the
region, other than rs17632542, that are independently
associated with PrCa, we used two different analytical
approaches. First, we used stepwise logistic regression
analyses of 7 SNPs in this region that were genotyped in all
stages and were significant at P \ 10-7. In this analysis,
one additional SNP, rs266849, remained in the model at
P \ 0.001 after adjusting for rs17632542 (P = 0.001,
Table 2) Secondly, we used the imputed data (Stages 1, 2
and CGEMS) and put all 35 SNPs significant at P \ 10-7
in a logistic regression analysis (Supplementary Table 2).
From this analysis, one SNP was significant at P \ 0.001
after adjusting for rs17632542 (either rs2659052 or
rs2569753, as both were correlated with one another,
r2 = 0.64). rs266849 is about 12 kb centromeric to
rs17632542 between the KLK15 and KLK3 genes.
rs266849 and rs2659052 were weakly correlated with each
other and with rs17632542 (Fig. 1; Supplementary
Table 3), suggesting that there are two additional associ-
ated variants. In both analyses, however, rs17632542
remained the most significantly associated SNP after
adjusting for the other significant SNPs (Table 2; Supple-
mentary Table 2).
Fig. 1 Regional LD plot and multiple transcripts of the KLK3 gene at 19q13.3. The newly identified SNPs associated with PrCa risk are labelled
using blue diamonds, two SNPs are intragenic in KLK3, rs17632542 is a coding variant in exon 4, rs 62113212 is in intron 3
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We previously reported that rs2735839 was associated
with serum PSA level (Eeles et al. 2008). Based on the
serum PSA levels of the stages 2 and 3 controls, the C
allele of rs17632542 was also associated with lower PSA
levels, with lowest levels in CC homozygotes
(P = 1.5 9 10-11, Supplementary Table 4; Supplemen-
tary Fig. 1). In a multiple regression analysis, rs2735839
was marginally significantly associated with PSA levels,
after adjusting for rs17632542 (P = 0.06). In a recent
publication (Gudmundsson et al. 2010) it was also reported
that at the KLK region rs17632542 was significantly
associated with PSA level and prostate cancer risk.
We found evidence for a significant association between
rs17632542 and Gleason score, with a stronger association
for lower grade disease (based on Gleason score\7 vs. 7?;
P-trend = 7.04 9 10-7 and based on Gleason score\8 vs.
8? P-trend 3.2 9 10-7, Supplementary Table 5). A simi-
lar association has previously been reported for rs2735839
(Kader et al. 2009). We found no association between
rs17632542 and family history or age of onset of the dis-
ease (data not shown).
Taken together, the above results suggest that observed
associations with both PrCa and PSA level are largely
driven by rs17632542 or rs62113212. These SNPs are
intragenic to KLK3: rs17632542 is a non-synonymous SNP
in exon 4 resulting in an Ile179Thr substitution, while
rs62113212 is intronic and lies in a sequence region with
no enhancer or splice effect function (Fig. 1). However,
based on the TFSEARCH database, http://www.cbrc.jp/
research/db/TFSEARCH.html, rs62113212 changes the
scores for the binding of the octamer factor 1 (Oct-1)
transcription factor. Although we cannot rule out
rs62113212 as the directly associated variant and it remains
possible that another correlated variant was missed by the
resequencing in the 1000 genomes dataset, rs17632542
appears to be the most plausible functional variant.
Based on the previous structural studies, 3D modeling
and X-ray crystallography of PSA and other kallikreins,
Ile179 is not part of the active catalytic site (Villoutreix
et al. 1994). However, when we carried out multiple
molecular dynamic simulations in explicit solvent, we
found that the solvated threonine (Thr) variant consistently
achieved lower energy levels compared with the isoleucine
(Ile) variant (-3,532 ± 54 kcal/mol compared with
-3,053 ± 41 kcal/mol), suggesting superior stability in
solution. Furthermore, modeling suggested that the Thr
variant causes displacement of the kallikrein loop (residues
111–118), although verification of this will require
empirical structural determination (Fig. 2).
Because multiple alternative transcripts have been
reported for KLK3 in normal and tumor-derived tissue
(Heuze-Vourc’h et al. 2003; Pampalakis et al. 2008;
Whitbread et al. 2010), we also assessed the possible effect
of the nucleotide substitution at the pre-mRNA level using
the Human Splice Finder bioinformatic prediction tool
(Desmet et al. 2009). New sites for exonic splice enhancer
motifs (SRp40, SRp55) were created in the presence of the
rs17632542 minor allele (C) by two algorithms. This
putative enhancer site is close to the splicing site for PSA-
RP2, a splice variant which results in retention of the intron
Fig. 2 Comparative molecular dynamic simulation of threonine and
isoleucine PSA variants. Structures shown are averaged from 10
independent simulations. a Ribbon diagram of I179T variant of PSA
coloured according to side chain displacement from the isoleucine
variant. Position of the catalytic triad is highlighted by a pink oval and
T179 substitution by a green oval. The kallikrein loop’s position is
indicated by a red rectangle. b Molecular surface view of I179T
variant PSA showing solvent accessible surface coloured according to
RMS displacement from wild-type (I179) PSA. Maximal displace-
ment is coloured red, whilst minimal displacement is blue as
indicated by the heat map
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between exons 3 and 4. Notably, the same splice variant is
found in four other KLK genes (Michael et al. 2005)
(KLK1, KLK2, KLK5 and KLK15) that surround KLK3 at
the centomeric end of the locus, suggesting this may be a
biologically important splicing event, given the evolu-
tionary conservation. Further molecular studies (EMSA,
luciferase assay) would be required to determine if this
SNP has an effect at the pre-mRNA level.
The contribution of common genetic variants in KLK3 to
PrCa risk has been a subject of considerable debate because
SNPs in this region were also found to be associated with
serum levels of PSA. The association seen for rs2735839 in
stage 1 of our GWAS could reflect the use of low PSA
controls. However, the association was also seen in stage 2
of the GWAS, in the CGEMS study, and in a validation
study of our GWAS results in 29 groups in the PRAC-
TICAL (Prostate cancer association group to investigate
cancer associated alterations in the genome) consortium in
56,300 samples (unpublished data), the majority of which
have not selected controls on the basis of PSA level. There
is still some potential for confounding due to opportunistic
PSA testing or testing as part of the diagnostic process. The
newly identified SNP, rs17632542, exhibits a more sig-
nificant association with PrCa than the previous tag SNP
and studies of this SNP in men who have prostate biopsy as
the primary PrCa screen, irrespective of PSA levels, could
determine whether this SNP is causally related to PrCa risk
independent of PSA. Given its stronger effect on PrCa risk,
inclusion of rs17632542 in place of rs2735839 in risk
prediction models will improve discrimination in such
models.
As this variant is predicted to introduce changes in the
stability of the protein and might have a role in pre-
mRNA processing of alternative transcripts; it is a good
candidate variant for further functional investigation of
the underpinnings of the GWAS signal in this region with
respect to PrCa risk. Similarly, additional studies are
required to determine if this coding variant also influences
PSA levels.
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